drugset
drugset / Trial / NCT05701774

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

NCT05701774 ↗

Phase 3 Active not recruiting 83 enrolled Soleno Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.

Timeline

Start
2023-01-31
Primary completion
2028-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Diazoxide Choline Unknown 75 mg Oral
Subject Diazoxide Choline Unknown 525 mg Oral

Indications

Prader-Willi syndrome